| Novel Trisubstituted Benzimidazoles, Targeting Mtb FtsZ, as a New Class of Antitubercular Agents K Kumar, D Awasthi, SY Lee, I Zanardi, B Ruzsicska, S Knudson, ... Journal of medicinal chemistry 54 (1), 374-381, 2011 | 200 | 2011 |
| GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human β cell regeneration C Ackeifi, P Wang, E Karakose, JE Manning Fox, BJ González, H Liu, ... Science translational medicine 12 (530), eaaw9996, 2020 | 113 | 2020 |
| Discovery of anti-TB agents that target the cell-division protein FtsZ K Kumar, D Awasthi, WT Berger, PJ Tonge, RA Slayden, I Ojima Future medicinal chemistry 2 (8), 1305-1323, 2010 | 106 | 2010 |
| SAR Studies on Trisubstituted Benzimidazoles as Inhibitors of Mtb FtsZ for the Development of Novel Antitubercular Agents D Awasthi, K Kumar, SE Knudson, RA Slayden, I Ojima Journal of medicinal chemistry 56 (23), 9756-9770, 2013 | 90 | 2013 |
| Drug discovery targeting cell division proteins, microtubules and FtsZ I Ojima, K Kumar, D Awasthi, JG Vineberg Bioorganic & medicinal chemistry 22 (18), 5060-5077, 2014 | 80 | 2014 |
| Development of kinase-selective, harmine-based DYRK1A inhibitors that induce pancreatic human β-cell proliferation K Kumar, P Wang, R Sanchez, EA Swartz, AF Stewart, RJ DeVita Journal of medicinal chemistry 61 (17), 7687-7699, 2018 | 72 | 2018 |
| Design, synthesis and evaluation of novel 2, 5, 6-trisubstituted benzimidazoles targeting FtsZ as antitubercular agents B Park, D Awasthi, SR Chowdhury, EH Melief, K Kumar, SE Knudson, ... Bioorganic & medicinal chemistry 22 (9), 2602-2612, 2014 | 65 | 2014 |
| Therapeutic potential of FtsZ inhibition: a patent perspective D Awasthi, K Kumar, I Ojima Expert opinion on therapeutic patents 21 (5), 657-679, 2011 | 61 | 2011 |
| DYRK1A inhibitors as potential therapeutics for β-cell regeneration for diabetes K Kumar, C Suebsuwong, P Wang, A Garcia-Ocana, AF Stewart, ... Journal of Medicinal Chemistry 64 (6), 2901-2922, 2021 | 58 | 2021 |
| Benzimidazole-based antibacterial agents against Francisella tularensis K Kumar, D Awasthi, SY Lee, JE Cummings, SE Knudson, RA Slayden, ... Bioorganic & medicinal chemistry 21 (11), 3318-3326, 2020 | 52 | 2020 |
| Synthesis and biological validation of a harmine-based, central nervous system (CNS)-avoidant, selective, human β-cell regenerative dual-specificity tyrosine phosphorylation … K Kumar, P Wang, J Wilson, V Zlatanic, C Berrouet, S Khamrui, C Secor, ... Journal of medicinal chemistry 63 (6), 2986-3003, 2020 | 52 | 2020 |
| Pharmacologic and genetic approaches define human pancreatic β cell mitogenic targets of DYRK1A inhibitors C Ackeifi, E Swartz, K Kumar, H Liu, S Chalada, E Karakose, DK Scott, ... JCI insight 5 (1), 2020 | 51 | 2020 |
| Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity K Kumar, PMU Ung, P Wang, H Wang, H Li, MK Andrews, AF Stewart, ... European journal of medicinal chemistry 157, 1005-1016, 2018 | 47 | 2018 |
| Human beta cell regenerative drug therapy for diabetes: past achievements and future challenges P Wang, E Karakose, L Choleva, K Kumar, RJ DeVita, A Garcia-Ocaña, ... Frontiers in Endocrinology 12, 671946, 2021 | 44 | 2021 |
| Targeting the hemopexin-like domain of latent matrix metalloproteinase-9 (proMMP-9) with a small molecule inhibitor prevents the formation of focal adhesion junctions VM Alford, A Kamath, X Ren, K Kumar, Q Gan, M Awwa, M Tong, ... ACS Chemical Biology 12 (11), 2788-2803, 2017 | 40 | 2017 |
| In vitro–in vivo activity relationship of substituted benzimidazole cell division inhibitors with activity against Mycobacterium tuberculosis SE Knudson, K Kumar, D Awasthi, I Ojima, RA Slayden Tuberculosis 94 (3), 271-276, 2014 | 35 | 2014 |
| A Trisubstituted Benzimidazole Cell Division Inhibitor with Efficacy against Mycobacterium tuberculosis SE Knudson, D Awasthi, K Kumar, A Carreau, L Goullieux, S Lagrange, ... PloS one 9 (4), e93953, 2014 | 28 | 2014 |
| Computer-aided identification, synthesis, and biological evaluation of novel inhibitors for botulinum neurotoxin serotype A YHG Teng, WT Berger, NM Nesbitt, K Kumar, TE Balius, RC Rizzo, ... Bioorganic & Medicinal Chemistry 23 (17), 5489-5495, 2015 | 24 | 2015 |
| Cell division inhibitors with efficacy equivalent to isoniazid in the acute murine Mycobacterium tuberculosis infection model SE Knudson, D Awasthi, K Kumar, A Carreau, L Goullieux, S Lagrange, ... Journal of Antimicrobial Chemotherapy 70 (11), 3070-3073, 2015 | 23 | 2015 |
| Study of antimicrobial activity of Rosa indica against gram positive and gram negative microorganisms U Kumar, K Kumar, CK Hindumathy International Journal of Microbiology Research 4 (3), 182, 2012 | 19 | 2012 |
Connie EavesTerry Fox Laboratory, BC Cancer Agency在 bccrc.ca 的电子邮件经过验证
